Kiniksa Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
100 Hayden Ave, Lexington, Massachusetts...Phone Number
(781) 431-9100Website
www.kiniksa.comRevenue
$754 MillionStock Symbol
KNSAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, founded in 2015 and headquartered in Hamilton, Bermuda, is a biopharmaceutical company dedicated to the discovery, acquisition, development, and commercialization of therapeutic medicines. The company specializes in diagnostic and health services, focusing on innovative treatments for various medical conditions. With operations across North America and Europe, Kiniksa Pharmaceuticals maintains a strong presence in the healthcare industry through its commitment to advancing medical solutions and therapeutic technologies. The company is publicly traded and continues to expand its portfolio of pharmaceutical products aimed at addressing unmet medical needs.Explore more
Kiniksa Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kiniksa Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Kiniksa Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Kiniksa Pharmaceuticals launches new products
Click to see if Kiniksa Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on Kiniksa Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Kiniksa Pharmaceuticals
Check out if Kiniksa Pharmaceuticals is spiking on competitors!
Check if Kiniksa Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Kiniksa Pharmaceuticals has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Kiniksa Pharmaceuticals
Compare insights from companies similar to Kiniksa Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$65.2M
201-500
Private
-
2015
LC
Lance CooperSenior Director, Lab Operations For Cytogenetics & Microarray
$23.9M
51-200
Private
$126.7M
2001
SB
Sofia BlehautAssociate Director and Regional Clinical Operations Manager
Company Profile Activity
Activity Insights
Kiniksa Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kiniksa Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals Tech Stack
A closer look at the technologies used by Kiniksa Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Kiniksa Pharmaceuticals has a Phase II dose-focusing study underway for KPL-387, comprising four arms designed to define the pharmacokinetic and pharmacodynamic relationship of the drug, including onset of action, magnitude and cadence of effect, and durability across different dosing intervals and peak and trough drug levels.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Kiniksa Pharmaceuticals has announced plans to accelerate KPL-1161, an Fc-modified monoclonal antibody targeting interleukin-1 alpha and beta inhibition with a target profile of a quarterly dosing regimen, into a Phase I clinical study by the end of this year.
Medical Research, Pharmaceuticals, Clinical Operations
Open Position
Open Position
Open Position
Kiniksa Pharmaceuticals News & Media
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 – – KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients – – Conference callKiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026
LONDON, July 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 28, 2026 at 8:30 a.m. Eastern Time to report its second quarter 2026 financial results and recent portfolio execution.Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 11:20 AM EDTCompany...Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in June:
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kiniksa Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Kiniksa Pharmaceuticals, founded in 2015 and headquartered in Hamilton, Bermuda, is a biopharmaceutical company dedicated to the discovery, acquisition, development, and commercialization of therapeutic medicines. The company specializes in diagnostic and health services, focusing on innovative treatments for various medical conditions. With operat... Read More
